Leverages the most advanced technology platform available for the creation of synthetically engineered, therapeutic microbes with the potential to make significant advancements in the treatment of disease

Sectors
Healthcare
Life Sciences
First Invested
2014
Seed
Company Status
IPO/Public
NASDAQ: SYBX
Board Members
Edward Mathers
Associated Team
Michael Albert